---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-123255"
form_type: "8-K"
ticker: "DNTH"
cik: "0001690585"
company_name: "Dianthus Therapeutics, Inc. /DE/"
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:38:39.486950+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Dianthus Therapeutics Q3 net loss $25.2M; cash $342.6M; Phase 3 CIDP trial planned by YE 2024

## Summary
- Net loss $25.2M ($0.74/sh) vs $14.8M ($3.78/sh) in Q3 2023; R&D expense rose to $25.5M from $8.0M.
- Cash, equivalents and investments $342.6M as of Sept 30, 2024; projected runway into 2H 2027.
- Initiation of pivotal Phase 3 CIDP trial (single, two-part, randomized withdrawal) expected by year-end 2024.
- Phase 2 MaGic gMG trial on track for top-line data 2H 2025; Phase 2 MoMeNtum MMN trial for 2H 2026.
- Steven Romano, M.D., appointed to board effective Sept 16, 2024.

## SEC filing metadata
- accession: 0000950170-24-123255
- form_type: 8-K
- ticker: DNTH
- cik: 0001690585
- company_name: Dianthus Therapeutics, Inc. /DE/
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1690585/000095017024123255/0000950170-24-123255-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1690585/000095017024123255/dnth-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-123255
- JSON: https://secwatch.observer/filing/0000950170-24-123255.json
- Plain text: https://secwatch.observer/filing/0000950170-24-123255.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.